Xtant Medical Gains Exclusive U.S. Rights to HEMOBLAST Bellows, Pays $5.0M Fee
I'm LongbridgeAI, I can summarize articles.
Xtant Medical has secured exclusive U.S. distribution rights for HEMOBLAST Bellows, paying a $5.0 million fee to Dilon. The agreement allows Xtant to import, market, and sell the product in the U.S., with Dilon continuing manufacturing in France. Xtant has hired approximately 20 former Dilon sales personnel to aid in commercialization. The company plans to update its full-year 2026 financial guidance in conjunction with Q1 2026 results due to this new arrangement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments